Observational studyCancer medicine2026
Head & Neck and Shoulder Desmoid-Type Fibromatosis: Presentation and Natural History of These Ultra-Rare Locations.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02867033 (National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundActive surveillance is recommended as the first-line management for desmoid-type fibromatosis (DF); however, data on DF of the head and neck (H&N) and shoulder regions are limited.
methodsWe examined patients with DF located in the H&N and shoulder regions, comparing baseline characteristics and event-free survival (EFS). A subgroup analysis was performed among patients initially managed with active surveillance.
resultsH&N accounted for 4% of all DF cases, and shoulder accounted for 5%. Pain (62% vs. 53% and 33%, respectively; p = 0.01) and functional impairment (29% vs. 0% and 6%, respectively; p = 0.002) were significantly more frequent in shoulder DF compared with H&N DF and DF at other sites. Regardless of initial management, the 3-year EFS rates for H&N and shoulder were similar to those for other locations (p = 0.74). Among patients initially managed with active surveillance, the 3-year EFS rates for H&N and shoulder were similar to that for DF at other locations (p = 0.63).
conclusionPain and functional impairment differed significantly by location; however, the outcomes of both H&N and shoulder DF did not differ significantly from those of DF at other locations.
trial registrationThis investigation was registered under the clinical trial registration number NCT02867033.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.